Kyntra Bio (KYNB) Ratios
Kyntra Bio Ratios
MX:KYNB's free cash flow for Q2 2026 was $-3.99M. For the 2026 fiscal year, MX:KYNB's free cash flow was increased by $0.00 and operating cash flow was $-3.99M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 3.39 | 1.47 | 1.52 | 1.80 | 2.10 |
| Quick Ratio | 3.26 | 1.45 | 1.33 | 1.65 | 1.96 |
| Cash Ratio | 1.64 | 0.38 | 0.52 | 0.57 | 0.76 |
| Solvency Ratio | 1.60 | -0.11 | -0.47 | -0.46 | -0.51 |
| Operating Cash Flow Ratio | -0.16 | -1.04 | -1.45 | -0.53 | -0.36 |
| Short-Term Operating Cash Flow Coverage | 0.00 | 0.00 | -7875.52 | 0.00 | 0.00 |
| Net Current Asset Value | $ -16.05M | $ -201.65M | $ -254.17M | $ -118.74M | $ -70.65M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.00 | 0.42 | 0.40 | 0.15 | 0.13 |
| Debt-to-Equity Ratio | 0.00 | -0.40 | -0.83 | -4.19 | 0.48 |
| Debt-to-Capital Ratio | 0.00 | -0.67 | -5.06 | 1.31 | 0.32 |
| Long-Term Debt-to-Capital Ratio | 0.00 | -0.66 | -0.78 | 0.00 | 0.00 |
| Financial Leverage Ratio | -3.98 | -0.95 | -2.07 | -28.45 | 3.70 |
| Debt Service Coverage Ratio | -6.56 | -17.24 | -37.49 | -196.65 | -310.76 |
| Interest Coverage Ratio | -5.24 | -18.24 | -39.87 | -209.05 | -268.40 |
| Debt to Market Cap | 0.00 | 0.07 | 0.04 | 0.00 | 0.00 |
| Interest Debt Per Share | 2.17 | 0.98 | 1.83 | 0.98 | 1.09 |
| Net Debt to EBITDA | 0.83 | -0.28 | -0.19 | 0.23 | 0.21 |
| Profitability Margins | |||||
| Gross Profit Margin | 91.37% | 47.47% | 91.53% | 85.59% | -90.89% |
| EBIT Margin | -905.19% | -489.92% | -673.31% | -208.50% | -148.12% |
| EBITDA Margin | -893.57% | -480.83% | -652.09% | -200.96% | -141.82% |
| Operating Profit Margin | -712.66% | -507.80% | -689.53% | -213.90% | -122.62% |
| Pretax Profit Margin | -905.19% | -517.76% | -690.60% | -208.40% | -123.10% |
| Net Profit Margin | 2848.63% | -160.63% | -607.29% | -208.66% | -123.25% |
| Continuous Operations Profit Margin | -903.79% | -516.86% | -690.06% | -208.66% | -123.25% |
| Net Income Per EBT | -314.70% | 31.02% | 87.94% | 100.12% | 100.12% |
| EBT Per EBIT | 127.02% | 101.96% | 100.16% | 97.43% | 100.40% |
| Return on Assets (ROA) | 153.40% | -22.18% | -67.11% | -48.13% | -37.48% |
| Return on Equity (ROE) | -610.73% | 21.09% | 139.22% | 1369.21% | -138.67% |
| Return on Capital Employed (ROCE) | -50.80% | -185.20% | -156.77% | -89.45% | -52.62% |
| Return on Invested Capital (ROIC) | -50.72% | -184.87% | -146.59% | -86.80% | -51.59% |
| Return on Tangible Assets | 153.40% | -22.18% | -67.11% | -48.13% | -37.48% |
| Earnings Yield | 516.80% | -3.59% | -13.18% | -0.78% | -0.89% |
| Efficiency Ratios | |||||
| Receivables Turnover | 1.53 | 61.58 | 1.14 | 8.63 | 9.26 |
| Payables Turnover | 0.15 | 3.07 | 0.22 | 0.66 | 17.21 |
| Inventory Turnover | 0.15 | 4.93 | 0.10 | 0.50 | 14.48 |
| Fixed Asset Turnover | 0.00 | 305.37 | 0.58 | 1.40 | 1.97 |
| Asset Turnover | 0.05 | 0.14 | 0.11 | 0.23 | 0.30 |
| Working Capital Turnover Ratio | 0.10 | 0.33 | 0.28 | 0.60 | 0.56 |
| Cash Conversion Cycle | 237.64 | -38.85 | 2494.77 | 216.46 | 43.40 |
| Days of Sales Outstanding | 238.95 | 5.93 | 320.16 | 42.27 | 39.40 |
| Days of Inventory Outstanding | 2457.19 | 74.00 | 3829.18 | 727.77 | 25.20 |
| Days of Payables Outstanding | 2458.50 | 118.78 | 1654.57 | 553.58 | 21.21 |
| Operating Cycle | 2696.14 | 79.93 | 4149.34 | 770.04 | 64.60 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -1.18 | -1.38 | -3.24 | -1.56 | -0.89 |
| Free Cash Flow Per Share | -1.19 | -1.38 | -3.26 | -1.97 | -1.22 |
| Dividend Paid and CapEx Coverage Ratio | -125.63 | -55.29 | -125.06 | -3.77 | -2.72 |
| Capital Expenditure Coverage Ratio | -125.63 | -518.79 | -125.06 | -3.77 | -2.72 |
| Operating Cash Flow Coverage Ratio | 0.00 | -1.53 | -1.85 | -1.62 | -0.82 |
| Operating Cash Flow to Sales Ratio | -0.74 | -4.66 | -6.73 | -1.04 | -0.35 |
| Free Cash Flow Yield | -13.56% | -10.43% | -14.73% | -0.49% | -0.35% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | 0.19 | -27.60 | -7.59 | -127.63 | -112.24 |
| Price-to-Sales (P/S) Ratio | 5.51 | 44.75 | 46.07 | 266.32 | 138.34 |
| Price-to-Book (P/B) Ratio | -1.18 | -5.88 | -10.56 | -1747.54 | 155.65 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -7.38 | -9.59 | -6.79 | -202.95 | -289.57 |
| Price-to-Operating Cash Flow Ratio | -7.44 | -9.61 | -6.84 | -256.83 | -395.87 |
| Price-to-Earnings Growth (PEG) Ratio | -0.00 | 0.33 | 1.04 | 0.00 | -2.28 |
| Enterprise Value Multiple | 0.22 | -9.59 | -7.25 | -132.29 | -97.33 |
| Enterprise Value | -12.37M | 1.37B | 2.21B | 37.41B | 32.48B |
| EV to EBITDA | 0.22 | -9.59 | -7.25 | -132.29 | -97.33 |
| EV to Sales | -1.92 | 46.09 | 47.28 | 265.85 | 138.04 |
| EV to Free Cash Flow | 2.57 | -9.87 | -6.97 | -202.59 | -288.94 |
| EV to Operating Cash Flow | 2.59 | -9.89 | -7.02 | -256.38 | -395.00 |
| Tangible Book Value Per Share | 1.11 | -1.84 | -1.67 | -0.02 | 2.48 |
| Shareholders’ Equity Per Share | -7.43 | -2.26 | -2.10 | -0.23 | 2.26 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.00 | 0.00 | 0.00 | -0.00 | -0.00 |
| Revenue Per Share | 1.59 | 0.30 | 0.48 | 1.50 | 2.55 |
| Net Income Per Share | 45.38 | -0.48 | -2.92 | -3.14 | -3.14 |
| Tax Burden | -3.15 | 0.31 | 0.88 | 1.00 | 1.00 |
| Interest Burden | 1.00 | 1.06 | 1.03 | 1.00 | 0.83 |
| Research & Development to Revenue | 3.65 | 3.23 | 5.69 | 2.11 | 1.64 |
| SG&A to Revenue | 4.30 | 1.67 | 0.00 | 0.00 | 0.00 |
| Stock-Based Compensation to Revenue | 1.02 | 0.85 | 1.08 | 0.47 | 0.30 |
| Income Quality | -0.03 | 2.90 | 1.11 | 0.50 | 0.28 |
Currency in USD
